Quantcast

Latest Diabetic retinopathy Stories

2011-05-04 15:05:00

MOUNTAIN VIEW, Calif., May 4, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the standard-of-care protocol for the treatment of eyes with diabetic macular edema (DME). The results indicated that treating using MicroPulse mode was as effective as the...

2011-05-02 08:30:00

TARRYTOWN, N.Y., May 2, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10, 2011 at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time). The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through May 27, 2011. Regeneron...

2011-05-01 00:09:06

WPI Communications announces the launch of a new publication for ophthalmologists. Short Hills, NJ (PRWEB) April 29, 2011 WPI Communications, an editorial and communications firm specializing in helping professionals increase revenue through expanded referrals, announced today the launch of Retina Update, a personalized quarterly educational newsletter designed to grab the attention of referring non-ophthalmic physicians. Retina Update gives practitioners a competitive advantage by...

2011-04-27 15:05:00

TARRYTOWN, N.Y. and BERLIN, April 27, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). The positive results from the GALILEO study confirm the results of the similarly designed Phase 3 COPERNICUS study that were announced in December 2010. In GALILEO,...

2011-04-25 13:50:00

WEST PALM BEACH, Fla., April 25, 2011 /PRNewswire/ -- The ophthalmic therapeutics company Xcovery Vision announced today that Sheridan G. Snyder, OBE, Chairman and CEO, and Dr. Ken Mandell, President and COO, will be speaking at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale Florida, May 1-5, 2011. Mr. Snyder's talk Perspective of a Serial Entrepreneur recounts his repeated success as founder of multiple biotech companies that include...

2011-04-20 15:01:23

Prospects for recovery of lost vision have brightened with the release of new scientific findings showing that the use of gentle near infra-red light can reverse damage caused by exposure to bright light, up to a month after treatment. The Vision Centre's Dr Krisztina Valter and doctoral researcher Rizalyn Albarracin have successfully demonstrated recovery of vision cells in the retina following near infra-red treatment applied after damage was sustained. Their advance has raised hopes for...

2011-04-13 05:30:00

RICHMOND, Va., April 13, 2011 /PRNewswire/ -- Richmond surgeon, Dr. Stewart O'Keefe, was recently elected as president of the Central Virginia Juvenile Diabetes Research Foundation's Board of Directors. As a Retina Surgeon at Retina Institute of Virginia (RIV) and Stony Point Surgery Center, Dr. O'Keefe performs over 500 surgeries each year, many for complications of diabetes such as diabetic macular edema. The Juvenile Diabetes Research Foundation (JDRF) has over 100 chapters worldwide,...

2011-04-13 00:00:27

Barnet Dulaney Perkins Eye Center is announcing a new Flagship Center to support the eye care needs of Arizona. The ophthalmologists and eye surgeons say the new center is located in Mesa, AZ, and is the most forward thinking eye care center in the state. Mesa, AZ (Vocus/PRWEB) April 12, 2011 The eye surgeons and ophthalmologists at Barnet Dulaney Perkins Eye Center (BDP) are announcing the opening of a new Flagship Center for eye care in Mesa, AZ. The doctors say their eye centers remain...

2011-04-08 08:44:00

In the news release, Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema, issued April 8, 2011 by Regeneron Pharmaceuticals, Inc. over PR Newswire, we are advised by a representative of the company that the seventh paragraph, second sentence, should read "In Europe, about 8% of the population is affected by diabetes" rather than "In Europe, about 8% of the population is affected by DME" as originally issued inadvertently. The complete, corrected release...

2011-04-08 01:30:00

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME). The companies are extending their development program for VEGF Trap-Eye in...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.